The Society On Sarcopenia, Cachexia & Wasting Disorders Announces Its 1st Cancer Cachexia Conference In Boston, USA
The Society on Sarcopenia, Cachexia and Wasting Disorders will hold its first ever Cancer Cachexia Conference in Boston, USA on September 21-23, 2012.
April 27, 2012 (Newswire.com) - The Society on Sarcopenia, Cachexia and Wasting Disorders will hold its first conference on cancer cachexia in Boston, MA, USA on September 21-23, 2012. The conference will gather more than 150 international researchers and clinicians who will attend educational sessions developed around the topic of cancer cachexia.
The Scientific Director of the project is Denis C. Guttridge, Ph.D. (Columbus, USA) of the Ohio Cancer Center.
Yann Colardelle, Executive Director of the SCWD is coordinator of the project at an international level, and acts as a liason with the many sponsors interested in providing their support for the program.
For further details on the program, please follow this link www.cachexia.org to view the full program agenda.
About the SCWD:
The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) was set up in 2008 as a nonprofit organization 501 (c) (3). Its mission is to increase awareness about Sarcopenia, Cachexia and Wasting Disorders, and to educate healthcare providers through the organization of educational activities with a multidisciplinary approach. The SCWD also tries to raise public awareness about the burden of these Wasting Disorders.
Cachexia is a complex metabolic syndrome associated with underlying illness and characterized by weight loss. Cachexia is common and occurs in over 50% of cancer patients and 90% of patients with pancreatic cancer. It represents a significant adverse health care issue and challenge for an increasing number of patients, their relatives and the medical teams who care for them.
Cachexia affects patients in a wide range of chronic medical conditions such as AIDS, cancer, chronic heart failure, chronic lung disease, liver cirrhosis, renal failure, rheumatoid arthritis, and sepsis. Its disease process involves a complex interaction between the disease and the body.
Cachexia is infrequently identified or diagnosed, and rarely treated As the treatment of diseases such as cancer, CHF, COPD, HIV infection, and kidney disease becomes increasingly effective, the diagnosis and treatment of Cachexia associated with these diseases will become important goals to improve morbidity, mortality, and particularly, the quality of life.
Active research is being developed in this field.
For additional information, contact Yann Colardelle of MedEd Global Solutions at:
Tel: +33142530303 - Fax: +33142530302
More information can be found online at http://www.cachexia.org